Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
HEPMAB: Heparin and Tocilizumab in Severe COVID-19
NCT04600141Phase 3Completed
- Sponsor
- Universidade de São Paulo
- Start
- Nov 2020
- Primary completion
- Oct 2021
- Modality
- Antibody Conjugates, Small Molecules, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
A Phase 3 trial of tocilizumab, heparin in coronavirus disease 2019 (COVID-19), sponsored by Universidade de São Paulo. Started Nov 2020; status: completed.
02
Drugs
tocilizumabheparin
03
Conditions
coronavirus disease 2019 (COVID-19)
Beyond the preview
Go deeper on NCT04600141.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04600141.